Protalix BioTherapeutics, Inc. (DE)

Good morning, ladies and gentlemen, and welcome to the Protallix BioTherapeutics Second Quarter 2026 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to your host, Mr. Mike Moyer of LifeSci Advisors, Investor Relations for Protallix. Please go ahead.

Thank you, Operator, and welcome to the Portalix BioTherapeutics Q2 2026 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO, and Gilad Mamlok, Senior Vice President and Chief Financial Officer. Press release announcing the financial results and corporate updates was issued this morning and is available now on the Portalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this conference Thank you Mike, and thank you everyone for joining me this morning.

Our results today reflect the strengths of our profitable commercial partnerships, and we remain confident in our outlook for this year. We enter the second half of 2026 with El Pablos sales through Chiesi, continuing to drive growth of our business. Gilad will walk through the financial details, but the key driver in the first half was continued growth in El Pablos revenues, together with the previously reported $25 million Yael Fellous, Yael Fellous, Yael Fellous, Yael Fellous, Yael Fellous, Yael Fellous, Yael Fellous, Yael Fellous, We believe our revenue mix, particularly the continuing expansion of Elfabrio, positions us well for sustained long-term value creation and profitability. On the clinical side, PRS 115 continues to advance its claim. PRX115 is designed as a long-acting differentiated uric acid, and we believe it has the potential to meaningfully improve quality of life for patients with uncontrolled gout, which could be a significant inflection point and venue driver for prosthetics. There is a significant unmet need in this population, and we expect top-line results from our release study in the second half of 2027. Beyond PRS 115, our strategy remains centered on rare renal diseases, where we believe our capabilities and platform offer a clear advantage, and we remain focused on execution across our partnerships and pipeline, and we believe our business model limits downside risks while preserving meaningful upside as we advance our clinical programs. With that, I will turn the call over to Gilad for a detailed review of our financial results and outlook.